DRUGDOCS | Triumeq®

Drug updated on 11/4/2024

Dosage Form	Tablet (oral; 600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine); PD Tablet (oral; 60 mg of abacavir, 5 mg of dolutegravir, and 30 mg of lamivudine)
Drug Class	Integrase strand transfer inhibitors [INSTI] and nucleoside analogue reverse transcriptase inhibitors [NRTI]
Ongoing and Completed Studies	ClinicalTrials.gov

Indication

Indicated for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 10 kg.

This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
The rate of virologic suppression (HIV-1 RNA < 50 copies/mL) and virologic failure (HIV-1 RNA ≥ 50 copies/mL) at Week 144 was similar across the DTG + 3TC, BIC/FTC/TAF, and DTG/ABC/3TC regimens.
In genital fluid HIV detection, 87% of participants on dual therapy (tenofovir/emtricitabine) and 93% on triple therapy had no detectable HIV in the TRULIGHT trial, while 80% on monotherapy (dolutegravir) and 81% on triple therapy showed no detectable HIV in the MONCAY trial; pooled analysis indicated 83% with no detectable HIV in lower drug regimens versus 87% in triple therapy.
There were no significant differences in mean changes in CD4+ cell count at Week 144 across DTG + 3TC, BIC/FTC/TAF, and DTG/ABC/3TC.
Serious adverse events were significantly less frequent with DTG + 3TC compared to BIC/FTC/TAF (OR, 0.51; 95% CI 0.29-0.87; P = 0.014) and DTG/ABC/3TC (OR, 0.38; 95% CI 0.19-0.75; P = 0.006); discontinuations and overall adverse events were similar across all regimens.
There were no specific safety outcomes or adverse effects reported in relation to LDRs versus triple therapies.
There is no population type or subgroup information available in the reviewed studies.

Document Title	Year	Source
Triumeq (abacavir, dolutegravir, lamivudine) Prescribing Information.	2022	ViiV Healthcare, Durham, NC

Document Title	Year	Source
An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1	2023	AIDS Research and Therapy
Genital Human Immunodeficiency Virus-1 RNA and DNA Shedding in Virologically Suppressed Individuals Switching From Triple- to Dual- or Monotherapy: Pooled Results From 2 Randomized, Controlled Trials	2020	Clinical Infectious Diseases

Document Title	Year	Source
Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States.	2024	National Institute of Health
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV	2024	National Institute of Health
European AIDS clinical society guidelines v12.0 October 2023.	2023	European AIDS Clinical Society